Quillaja saponin-based adjuvant specialist Q-VANT Biosciences announced that Kansas University College of Veterinary Medicine will test its adjuvants in several of its veterinary vaccines.
The project’s first focus will test Q-VANT’s sustainable saponin-based adjuvants against other adjuvants using K-State’s subunit classic swine fever (CSF) vaccine.
The Kansas University researchers will also validate the safety and efficacy of other Quillaja saponin-based adjuvants from Q-VANT.
[Related: Q-VANT aims to rewrite the narrative for Quillaja saponin-based adjuvants.]
Kansas University is also home to the Biosecurity Research Institute, a comprehensive infectious disease high-security research facility.
The CSF vaccine that will be the initial focus of the research was developed by professor Jishu Shi, a professor within the school’s College of Veterinary Medicine who focuses on developing strategies to protect against swine infectious diseases.
“This partnership is an exciting opportunity for all involved,” said Shi. “Our students will have the opportunity to take part in a research project that has the potential to have a major positive impact globally in animal vaccine development and usage.”
Q-VANT has developed a sustainable method of producing the QS-21 saponin adjuvant, which is present in GSK’s (NYSE:GSK) Shingrix shingles vaccine, GSK’s Mosquirix malaria vaccine and Novavax’s (NSDQ:NVAX) COVID-19 vaccine.
Clinicaltrials.gov cites 55 studies using the adjuvant.
Filed Under: Drug Discovery and Development, Infectious Disease
